Direct inhibitors of Lp-PLA2 are currently undergoing clinical trials, and if they prove to reduce the necrotic core area of a rupture-prone plaque, they will solidify the importance of Lp-PLA2 as a therapeutic target for the management of atherosclerosis and prevention of myocardial infarction, stroke, and cardiovascular death. This evidence concerns the gene PLA2G7 and myocardial infarction.